Epoetin alpha every 2 weeks vs to weekly
Adverse events: thrombovascular events · anaemia in predialysis patients
Epoetin alpha every 2 weeks showed no clear difference in adverse events: thrombovascular events compared with to weekly (low certainty).
1 finding from 1 review
- Short‐acting erythropoiesis‐stimulating agents for anaemia in predialysis patients 2017 · Cochrane Headline outcomes onlyRR 1.41 [0.67, 3]4 studies · 838 participantsLow